We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Blocking Insulin-degrading Enzyme Reverses Diabetes Symptoms in Mouse Model

By LabMedica International staff writers
Posted on 15 Jun 2014
Print article
Image: Molecular model shows how the inhibitor binds to Insulin Degrading Enzyme (IDE). The inhibitor is depicted in orange and white spheres. IDE is depicted as the blue and green surface, and the gray ribbons (Photo courtesy of Dr. Markus Seeliger, Stony Brook University).
Image: Molecular model shows how the inhibitor binds to Insulin Degrading Enzyme (IDE). The inhibitor is depicted in orange and white spheres. IDE is depicted as the blue and green surface, and the gray ribbons (Photo courtesy of Dr. Markus Seeliger, Stony Brook University).
Determination of the structure of insulin-degrading enzyme (IDE) by X-ray crystallography paved the way for its successful inhibition and the easing of symptoms in a mouse model of type II diabetes.

The IDE gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates its activity, as well as participating in intercellular peptide signaling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. The preferential affinity of this enzyme for insulin results in insulin-mediated inhibition of the degradation of other peptides such as beta-amyloid. Deficiencies in this protein's function are associated with Alzheimer's disease and type II diabetes mellitus but mutations in this gene have not been shown to be causative for these diseases. This protein localizes primarily to the cytoplasm but in some cell types localizes to the extracellular space, cell membrane, peroxisome, and mitochondrion.

Investigators at Stony Brook University (NY, USA) and colleagues at Harvard University (Cambridge, MA, USA) and Brookhaven National Laboratory (Upton, NY, USA) reported in the May 21, 2014, online edition of the journal Nature that they had discovered a physiologically active IDE inhibitor from a DNA-templated macrocycle library. An X-ray structure of the macrocycle bound to IDE revealed that it engaged a binding pocket away from the catalytic site, which explained its remarkable selectivity.

Treatment of lean and obese mice with this inhibitor showed that IDE regulated the abundance and signaling of glucagon and amylin, in addition to that of insulin. Under physiological conditions that increased insulin and amylin levels, such as oral glucose administration, acute IDE inhibition led to substantially improved glucose tolerance and slower gastric emptying.

"A strategy to protect the remaining amounts of insulin produced by diabetics in response to blood sugar levels is an attractive treatment alternative, particularly in the early stages of type II diabetes,” said contributing author Dr. Markus Seeliger, assistant professor of pharmacological sciences at Stony Brook University. “The research results give proof of concept that targeting this protein is extremely promising. The inhibitor we discovered successfully relieved the symptoms of type II diabetes in obese mice and not only elevated their insulin levels but promoted healthy insulin signaling within the blood.”

Related Links:

Stony Brook University
Harvard University
Brookhaven National Laboratory


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Cortisol Rapid Test
Finecare Cortisol Rapid Quantitative Test
New
Urine Drug Test
Instant-view Methadone Urine Drug Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Genome sequencing technology has the potential to detect thousands of genetic disease (Photo courtesy of 123RF)

Gene Technology Outperforms Standard Newborn Screening Tests in Pioneering Study

Since its introduction in the 1960s, newborn screening has grown to encompass dozens of primarily genetic disorders. The standard approach to newborn screening involves detecting specific biomarkers in... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.